IDH2 and acute myeloid leukemia: Enasidenib also received approval for adults with R/R IDH2-mutated AML after the promising results of Stein et al. who showed an ORR of 40% and CR rate of 19% in a cohort of 199 patients treated with 100 mg orally daily [50].